Cargando…

Lysine methyltransferase inhibitors: where we are now

Protein lysine methyltransferases constitute a large family of epigenetic writers that catalyse the transfer of a methyl group from the cofactor S-adenosyl-l-methionine to histone- and non-histone-specific substrates. Alterations in the expression and activity of these proteins have been linked to t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feoli, Alessandra, Viviano, Monica, Cipriano, Alessandra, Milite, Ciro, Castellano, Sabrina, Sbardella, Gianluca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	RSC 2021
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985178/ https://www.ncbi.nlm.nih.gov/pubmed/35441141 http://dx.doi.org/10.1039/d1cb00196e

Ejemplares similares

The emerging role of lysine methyltransferase SETD8 in human diseases
por: Milite, Ciro, et al.
Publicado: (2016)

NADPH Oxidases: From Molecular Mechanisms to Current Inhibitors
por: Cipriano, Alessandra, et al.
Publicado: (2023)

Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction–Reconstruction and Fragment-Growing Approach
por: Iannelli, Giulia, et al.
Publicado: (2022)

Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor
por: Feoli, Alessandra, et al.
Publicado: (2023)

Discovery of Benzo[d]imidazole‐6‐sulfonamides as Bromodomain and Extra‐Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain
por: Cipriano, Alessandra, et al.
Publicado: (2022)

Synthesis of lysine methyltransferase inhibitors
por: Hui, Chunngai, et al.
Publicado: (2015)

Novel 2-substituted-benzimidazole-6-sulfonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IX and XII and molecular docking studies
por: Milite, Ciro, et al.
Publicado: (2019)

Aging with Down Syndrome—Where Are We Now and Where Are We Going?
por: Alldred, Melissa J., et al.
Publicado: (2021)

Aromatase inhibitors--where are we now?
por: Miller, W. R.
Publicado: (1996)

Angiogenesis inhibitors in clinical development; where are we now and where are we going?
por: Eskens, F A L M
Publicado: (2004)

Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023)

Where are we now?
Publicado: (1977)

NIPPV: Where Are We Now?
por: Fakharian, Atefeh, et al.
Publicado: (2013)

Onchodermatitis: Where Are We Now?
por: Murdoch, Michele E.
Publicado: (2018)

AI in medicine: Where are we now and where are we going?
por: Shandhi, Md Mobashir Hasan, et al.
Publicado: (2022)

Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to?
por: Wasilewicz, Michał P., et al.
Publicado: (2023)

Metformin and Breast Cancer: Where Are We Now?
por: Cejuela, Mónica, et al.
Publicado: (2022)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
por: Tovoli, Francesco, et al.
Publicado: (2020)

Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going
por: Mazzitelli, Carlotta, et al.
Publicado: (2023)

Atypical Chronic Myeloid Leukemia: Where Are We Now?
por: Crisà, Elena, et al.
Publicado: (2020)

Vesicoureteral Reflux: Where Have We Been, Where Are We Now, and Where Are We Going?
por: McLorie, Gordon A.
Publicado: (2008)

Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
por: Jang, Albert, et al.
Publicado: (2021)

Platelet-Rich Plasma: Where Are We Now and Where Are We Going?
por: Cole, Brian J., et al.
Publicado: (2010)

Ten Years for GHSP: Where Are We Now? Where Will We Go?
por: Bhutta, Zulfiqar A., et al.
Publicado: (2023)

Targeting therapy in pemphigus: Where are we now and where are we going?
por: Abulikemu, Kailibinuer, et al.
Publicado: (2023)

CAR-T cell therapy: Where are we now, and where are we heading?
por: Wang, Jia-Yi, et al.
Publicado: (2023)

First-in-Class Selective Inhibitors of the Lysine Acetyltransferase KAT8
por: Fiorentino, Francesco, et al.
Publicado: (2023)

Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization
por: Fattore, Luigi, et al.
Publicado: (2020)

Age-dependent attenuation of spatial memory deficits by the histone acetyltransferase p300/CBP-associated factor (PCAF) in 3xTG Alzheimer's disease mice
por: Creighton, Samantha D., et al.
Publicado: (2022)

Pegfilgrastim Biosimilars: Where Are We Now?
por: Selby, Christopher, et al.
Publicado: (2021)

Osteopontin and Transplantation: Where Are We Now?
por: Kaleta, Beata
Publicado: (2021)

Epilepsy and psychosis– where are we now?
por: Pereira, I., et al.
Publicado: (2021)

Depression research: where are we now?
por: Lee, Saebom, et al.
Publicado: (2010)

Personal workstations: Where are we now?
por: Willers, Ian Malcolm
Publicado: (1982)

Personal genomics: Where are we now?
por: Angrist, Misha
Publicado: (2016)

9. GFR - Where are We Now?
por: Delanghe, Joris R.
Publicado: (2009)

Calcaneal fractures: Where are we now?
por: Razik, Aisha, et al.
Publicado: (2017)

Intracranial Atherosclerosis: Where Are We Now?
por: Kim, Jong S.
Publicado: (2017)

Mindfulness in psychiatry – where are we now?
por: Groves, Paramabandhu
Publicado: (2016)

MHC Restriction: Where Are We Now?
por: Zareie, Pirooz, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_eq6plfffpo8oh90mpkj0ua43sv